New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...

The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

Wolfe projects a positive outlook for Pharma & Large-Cap Biotech stocks despite potential policy changes as part of Make America Healthy Again movement. Read more here.

Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.